Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino
Conditions: Pancreatic Cancer Interventions: Drug: Adebrelimab; Drug: mRNA tumor vaccines Sponsors: Fudan University; Shanghai Regenelead Therapies Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Pancreas | Pancreatic Cancer | Research | Study | Vaccines